Optimisation of aceclofenac fast dissolving tablets employing starch xanthate using 23 factorial design
Abstract
The present study involves in the evaluation of starch xanthate as a superdintegrant in the formulation of fast dissolving tablets of poorly soluble drugs employing 23factorial design. By using gelatinization process starch xanthate was synthesized. Then the synthesized starch xanthate was evaluated under physical and micromeritic methods. To develop starch xanthate as a superdisintegrant, fast dissolving tablet of aceclofenac was prepared by direct compression method employing starch xanthate in different proportions in each case employing 23 factorial design. All the prepared fast dissolving tablets were evaluated for drug content, hardness, friability, disintegration time and other dissolution characteristics like PD10, DE5 and K1. The prepared starch xanthate was found to be fine, free flowing slightly crystalline powder. Starch xanthate shown good swelling in water. The swelling index was 50% and all micrometric properties shown good flow and compressibility needed for solid dosage from manufacturing. All the formulated fast dissolving tablets employing starch xanthate were of good quality with regard to drug content, hardness and friability and fulfilled the official (IP/USP) requirements of compressed tablets with regard to the above mentioned physical properties. Starch xanthate was found to be a superdisintegrant which enhanced the dissolution efficiency when combined with croscarmellose sodium, with the aceclofenac and hence it could be utilized in the formulation of fast dissolving tablets to provide immediate release of the contained drug within 10 minutes.
Keywords: Fast Dissolving, Superdisintegrant, Starch xanthate, Dissolution efficiency
Downloads
References
2. Seager H. Drug delivery product and zydis-fast dissolving dosage form. J Pharm Pharmacol 1998; 50: 375-82.
3. Abdelbary G, Prinderre P, Couani C, Taochim J, Reynier JP, Riccerelle P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int J Pharm 2004; 278:423-33.
4. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery: a review. Pharm Sci Techol Today 2000; 3:138-45.
5. Lachman L, Libermann HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd edition; 1991. p. 233-5.
6. Biradar S, Bhagavati S, Kuppasad I. Fast dissolving drug delivery system: A brief overview. Internet J Pharmacol 2005; 4:2. edition; 1991. p. 233-5.
7. Indurwade NH, Rajyaguru TH, Nakhat PD. Noval approach-fast dissolving tablets. Indian Drug 2002; 38:405-9.
8. The United States Pharmacopoeia 29, National Formulary 24, Asian Edition. Rockville, MD: United States Pharmacopoeia Convention, Inc; 2006. p. 1890.
9. Jacob S, Shirwaikar A, Joseph A, Srinivasan KK. Novel co-processed excipient of lactose and microcrystalline callous for preparing fast dissolving tablet of Glipizide. Indian J Pharm Sci 2007; 69:633-9.
10. Hiremath JG, Shastry CS, Srinath MS. Pharmaceutical approaches of taste masking in oral dorage forms. Indian Drugs 2004; 41: 253-7.
11. Abdelbary A, Elshafeey AH, Zidan G. Comparative effects of different cellulosic-based directly compressed orodispersible tablets on oral bioavailability of famotidine. Carbohydrate Polymers 2009; 77:799-806.
12. Battu SK, Michael AR, Soumyajit M, Madhusudan Y. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of super disintegrants. Drug Dev Ind Pharm 2007; 33:1225-32.
13. Goel H, Vora N, Rana V. A novel approach to optimize and formulate fast disintegrating tablets for nausea and vomiting. AAPS PharmSciTech 2008; 9:774–8.
14. Puttewar TY, Kshirsagar MD, Chandewar AV, Chikhale RV. Formulation and evaluation of orodispersible tablet of taste masked doxylamine succinate using ion exchange resin. J King Saud University (Sci) 2010; 22:229–40.
15. Manohara P, Trivikrama bhatlu M, Kiran kumar P V, Bala krishna N, Murali krishna Ranga. Formulation and evaluation of aceclofenac fast disintegrating tablets in the design Hordeum Vulgare Hull. Journal of Pharmacy Research 2012; 5:657-660.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).